BTCY vs. RES

Last updated Jun 3, 2026

BTCY (Biotricity, Inc.) and RES (RPC, Inc.) are both stocks. BTCY operates in Medical Devices (Healthcare), while RES operates in Oil & Gas Equipment & Services (Energy). Over the past 10 years, BTCY returned -33.60%/yr vs -5.84%/yr for RES. At a 0.01 correlation, their price movements are largely independent.

Performance

BTCY vs. RES - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Biotricity, Inc. (BTCY) and RPC, Inc. (RES). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BTCY achieves a -53.33% return, which is significantly lower than RES's 29.98% return. Over the past 10 years, BTCY has underperformed RES with an annualized return of -33.60%, while RES has yielded a comparatively higher -5.84% annualized return.

BTCY

• 1D: 22.59%
• 1M: -46.73%
• YTD: -53.33%
• 6M: -72.14%
• 1Y: -73.58%
• 3Y*: -67.82%
• 5Y*: -62.01%
• 10Y*: -33.60%

RES

• 1D: 2.65%
• 1M: -7.86%
• YTD: 29.98%
• 6M: 30.94%
• 1Y: 59.68%
• 3Y*: 1.01%
• 5Y*: 4.78%
• 10Y*: -5.84%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BTCY vs. RES - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BTCY Biotricity, Inc.	-53.33%	3.50%	-74.80%	-57.22%	-88.74%	439.11%	17.18%	31.25%	-93.68%	194.22%
RES RPC, Inc.	29.98%	-5.49%	-16.39%	-16.42%	96.73%	44.13%	-39.89%	-46.14%	-60.21%	29.61%

Correlation

The correlation between BTCY and RES is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.01
Correlation (5Y) Calculated over the trailing 5-year period	0.04
Correlation (10Y) Calculated over the trailing 10-year period	0.01
Correlation (All Time) Calculated using the full available price history since Feb 19, 2016	0.01

Fundamentals

Market Cap BTCY : $3.86M RES : $1.54B
EPS BTCY : -$0.17 RES : $0.10
PS Ratio BTCY : 0.24 RES : 0.87
Total Revenue (TTM) BTCY : $15.45M RES : $1.75B
Gross Profit (TTM) BTCY : $12.53M RES : $242.68M
EBITDA (TTM) BTCY : $267.47K RES : $218.68M

Return for Risk

BTCY vs. RES — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BTCY

BTCY Risk / Return Rank: 13
BTCY Sharpe Ratio Rank: 16
BTCY Sortino Ratio Rank: 19
BTCY Omega Ratio Rank: 20
BTCY Calmar Ratio Rank: 7
BTCY Martin Ratio Rank: 4

RES

RES Risk / Return Rank: 76
RES Sharpe Ratio Rank: 77
RES Sortino Ratio Rank: 70
RES Omega Ratio Rank: 72
RES Calmar Ratio Rank: 81
RES Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTCY vs. RES - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Biotricity, Inc. (BTCY) and RPC, Inc. (RES). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BTCY	RES	Difference
Sharpe ratio Return per unit of total volatility	-0.55	1.29	-1.84
Sortino ratio Return per unit of downside risk	-0.48	1.78	-2.26
Omega ratio Gain probability vs. loss probability	0.95	1.24	-0.30
Calmar ratio Return relative to maximum drawdown	-0.87	2.97	-3.84
Martin ratio Return relative to average drawdown	-1.55	6.34	-7.89
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BTCY vs. RES - Sharpe Ratio Comparison

The current BTCY Sharpe Ratio is -0.55, which is lower than the RES Sharpe Ratio of 1.29. The chart below compares the historical Sharpe Ratios of BTCY and RES, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BTCY	RES	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.55	1.29	-1.84
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.49	0.09	-0.58
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.26	-0.10	-0.16
Sharpe Ratio (All Time) Calculated using the full available price history	-0.28	0.20	-0.49

Drawdowns

BTCY vs. RES - Drawdown Comparison

The maximum BTCY drawdown since its inception was -99.83%, which is greater than RES's maximum drawdown of -92.34%. Use the drawdown chart below to compare losses from any high point for BTCY and RES.

Drawdown Indicators

	BTCY	RES	Difference
Max Drawdown Largest peak-to-trough decline	-99.83%	-92.34%	-7.49%
Max Drawdown (1Y) Largest decline over 1 year	-85.91%	-20.83%	-65.08%
Max Drawdown (3Y) Largest decline over 3 years	-97.59%	-51.93%	-45.66%
Max Drawdown (5Y) Largest decline over 5 years	-99.63%	-63.75%	-35.88%
Max Drawdown (10Y) Largest decline over 10 years	-99.83%	-92.34%	-7.49%
Current Drawdown Current decline from peak	-99.77%	-70.05%	-29.72%
Average Drawdown Average peak-to-trough decline	-76.01%	-37.49%	-38.52%
Ulcer Index Depth and duration of drawdowns from previous peaks	48.07%	9.75%	+38.32%

Volatility

BTCY vs. RES - Volatility Comparison

Biotricity, Inc. (BTCY) has a higher volatility of 61.97% compared to RPC, Inc. (RES) at 12.55%. This indicates that BTCY's price experiences larger fluctuations and is considered to be riskier than RES based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BTCY	RES	Difference
Volatility (1M) Calculated over the trailing 1-month period	61.97%	12.55%	+49.42%
Volatility (6M) Calculated over the trailing 6-month period	95.52%	36.06%	+59.46%
Volatility (1Y) Calculated over the trailing 1-year period	133.15%	46.64%	+86.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	126.95%	52.93%	+74.02%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	130.35%	57.34%	+73.01%

Dividends

BTCY vs. RES - Dividend Comparison

BTCY has not paid dividends to shareholders, while RES's dividend yield for the trailing twelve months is around 2.29%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BTCY Biotricity, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
RES RPC, Inc.	2.29%	2.94%	2.69%	2.20%	0.45%	0.00%	0.00%	2.86%	4.76%	0.51%	0.25%	1.30%

Financials

BTCY vs. RES - Profitability Comparison

The chart below illustrates the profitability comparison between Biotricity, Inc. and RPC, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BTCY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Biotricity, Inc. reported a gross profit of 3.25M and revenue of 3.99M. Therefore, the gross margin over that period was 81.5%.

RES - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, RPC, Inc. reported a gross profit of 99.17M and revenue of 454.76M. Therefore, the gross margin over that period was 21.8%.

BTCY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Biotricity, Inc. reported an operating income of 440.92K and revenue of 3.99M, resulting in an operating margin of 11.1%.

RES - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, RPC, Inc. reported an operating income of 2.62M and revenue of 454.76M, resulting in an operating margin of 0.6%.

BTCY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Biotricity, Inc. reported a net income of -1.15M and revenue of 3.99M, resulting in a net margin of -28.8%.

RES - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, RPC, Inc. reported a net income of 855.00K and revenue of 454.76M, resulting in a net margin of 0.2%.

Frequently Asked Questions

Can I hold both BTCY and RES in my portfolio?

BTCY and RES have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BTCY or RES?

BTCY has higher volatility (61.97%) compared to RES (12.55%). In terms of maximum drawdown, BTCY dropped -99.83% vs RES's -92.34%.

Which has better risk-adjusted returns?

RES currently has the higher Sharpe Ratio (1.29 vs -0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.